Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
AKRO
Stock Latest News
Ratings
Strategic Value and Market Positioning Drive Buy Rating for Akero Therapeutics
22h ago
AKRO
Premium
The Fly
Akero Therapeutics assumed with a Buy at H.C. Wainwright
15d ago
AKRO
Premium
Company Announcements
Akero Therapeutics’ Efruxifermin Study: A Potential Game-Changer for NASH Treatment
30d ago
AKRO
Premium
Company Announcements
Akero Therapeutics’ Phase 3 NASH Study: A Potential Game-Changer?
1M ago
AKRO
Premium
The Fly
Akero Therapeutics’ efruxifermin shows efficacy in Phase 2b MASH, fibrosis trial
1M ago
AKRO
Premium
Ratings
Strong Financial Position and Promising Clinical Developments Support Buy Rating for Akero Therapeutics
1M ago
AKRO
Premium
Company Announcements
Akero Therapeutics Advances in MASH Treatment Development
1M ago
AKRO
Premium
Ratings
Ritu Baral Recommends Buy Rating for Akero Therapeutics Amid Promising Clinical Trials and Strong Financial Position
1M ago
AKRO
Premium
Ratings
Akero Therapeutics Positioned as Leader in MASH Treatment with Efruxifermin Advancements
1M ago
AKRO
Premium
The Fly
Video: Why Akero Therapeutics Is Trading Higher Today
1M ago
NVO
AKRO
Premium
The Fly
Morgan Stanley says zalfermin discontinuation has positive readthrough for Akero
1M ago
NVO
AKRO
Premium
Pre-Earnings
AKRO Earnings Report this Week: Is It a Buy, Ahead of Earnings?
1M ago
AKRO
Premium
The Fly
Coinbase downgraded, Spotify upgraded: Wall Street’s top analyst calls
2M ago
AVB
BAX
Premium
The Fly
Akero Therapeutics initiated with a Buy at TD Cowen
2M ago
AKRO
Premium
Company Announcements
Akero Therapeutics Advances Efruxifermin Study for NASH Treatment
2M ago
AKRO
Premium
Company Announcements
Akero Therapeutics Advances Phase 3 Study on Efruxifermin for NASH/MASH Cirrhosis
2M ago
AKRO
Premium
Company Announcements
Akero Therapeutics Advances Phase 3 Study on Efruxifermin for NASH/MASH Treatment
2M ago
AKRO
Premium
Company Announcements
Akero Therapeutics’ Efruxifermin Study: A Potential Game-Changer for NASH/MASH Treatment
3M ago
AKRO
Premium
The Fly
Jefferies sees Akero, Scholar Rock as ‘promising’ takeover targets
3M ago
LLY
MRK
Premium
The Fly
Warner Bros. Discovery to split up, Qualcomm buying Alphawave Semi: Morning Buzz
3M ago
CCJ
COE
Premium
The Fly
Akero Therapeutics rumor highlighted in Betaville blog
3M ago
AKRO
Premium
Company Announcements
Akero Therapeutics Elects New Directors at Annual Meeting
4M ago
8K
AKRO
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >
You need to enable JavaScript to run this app.
